BHC - Bausch Health Companies Inc.

NYSE - NYSE Delayed Price. Currency in USD
19.37
+0.27 (+1.41%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Commodity Channel Index

Commodity Channel Index

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close19.10
Open19.16
Bid0.00 x 1800
Ask0.00 x 1100
Day's Range19.14 - 19.90
52 Week Range11.15 - 31.97
Volume4,871,418
Avg. Volume6,344,296
Market Cap6.85B
Beta (5Y Monthly)0.87
PE Ratio (TTM)N/A
EPS (TTM)-1.75
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateNov 10, 2010
1y Target Est26.82
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • FDA Provides 510(k) Clearance For BAUSCH + LOMB INFUSE™ Daily Disposable Silicone Hydrogel (SiHy Daily) Contact Lenses
    PR Newswire

    FDA Provides 510(k) Clearance For BAUSCH + LOMB INFUSE™ Daily Disposable Silicone Hydrogel (SiHy Daily) Contact Lenses

    Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for BAUSCH + LOMB INFUSE™ daily disposable silicone hydrogel (SiHy daily) contact lenses.

  • Hedge Funds Are Getting Crazy About Bausch Health Companies (BHC)
    Insider Monkey

    Hedge Funds Are Getting Crazy About Bausch Health Companies (BHC)

    Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out […]

  • Thomson Reuters StreetEvents

    Edited Transcript of BHC earnings conference call or presentation 7-May-20 12:00pm GMT

    Q1 2020 Bausch Health Companies Inc Earnings Call

  • 2 Healthcare Stocks At High Risk Of A Writedown
    Motley Fool

    2 Healthcare Stocks At High Risk Of A Writedown

    Investing in companies that are forced to write down their assets due to botched acquisitions can have devastating consequences for investors.

  • Bausch + Lomb Announces The European Launch Of LuxSmart™ And LuxGood™ Preloaded Intraocular Lenses
    PR Newswire

    Bausch + Lomb Announces The European Launch Of LuxSmart™ And LuxGood™ Preloaded Intraocular Lenses

    Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), today announced the European launch of the company's first Extended Depth of Focus intraocular lens (IOL), LuxSmart™, and a new monofocal IOL, LuxGood™. Both feature preloaded delivery systems and Pure Refractive Optics (PRO) Technology.

  • Barrons.com

    Anterix and Bausch Holding See Activist Action

    Owl Creek Asset Management increased its stake in wireless-communications firm Anterix, while Paulson & Co. bought more Bausch stock.

  • Francis Chou Slims 4 Positions in the 1st Quarter
    GuruFocus.com

    Francis Chou Slims 4 Positions in the 1st Quarter

    Canadian guru releases portfolio. Sells include major Berkshire bank holding Bank of America. Continue reading...

  • Bausch Health To Participate At Goldman Sachs Annual Global Healthcare Conference
    PR Newswire

    Bausch Health To Participate At Goldman Sachs Annual Global Healthcare Conference

    Bausch Health Companies Inc. (NYSE/TSX: BHC) today announced that Joseph C. Papa, chairman and chief executive officer, and Arthur J. Shannon, senior vice president and head of Investor Relations and Communications, are scheduled to participate at the virtual Goldman Sachs Annual Global Healthcare Conference on June 10, 2020, at 3:50 p.m. EDT.

  • Mario Gabelli Adds to Amazon Holding in 1st Quarter
    GuruFocus.com

    Mario Gabelli Adds to Amazon Holding in 1st Quarter

    An overview of the guru's top 5 buys Continue reading...

  • Notable Insider Buys: Bausch, TransDigm And More
    Benzinga

    Notable Insider Buys: Bausch, TransDigm And More

    * Insider buying can be an encouraging signal for potential investors. * Directors stepped up to make sizable share purchases last week. * Some of those transactions came in the wake of earnings reports.Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider buying can be an encouraging signal for potential investors, particularly during periods of uncertainty.Insiders continued to add shares despite overall market volatility and global economic gloom.Here are some of the most noteworthy insider purchases reported in the past week.TransDigm A TransDigm Group Incorporated (NYSE: TDG) director indirectly added almost 372,000 shares of this aircraft component maker to his stake. At per-share prices ranging from $309.87 to $354.34, that totaled more than $125.18 million. Note that another director purchased 2,000 shares in the previous week.The company posted better than expected fiscal second-quarter earnings earlier this month. The stock ended last week's trading at $325 per share, still within the director's purchase price range. The share price is only up 3% or so since its year-to-date low in March.Bausch Health Bausch Health Companies Inc (NYSE: BHC) saw a director indirectly purchase nearly 5 million shares of this specialty pharmaceutical company last week at between $15.85 and $17.50 a share. That cost that director more than $83.25 million and raised his stake to almost 25.85 million shares.This Canada-based company priced and upsized a previously announced stock offering last week. The shares ended last week down over 6% to $15.74. That's below the director's purchase price range. However, the stock is up about 7% from the year-to-date low seen in March.Aon A director at Aon PLC (NYSE: AON) stepped up to the buy window in the wake of better than expected first-quarter results posted at the start of the month. The director indirectly bought 70,000 shares midweek for $195.00 apiece, which totaled $13.65 million. This raised his stake to 100,000 shares.Shares of this London-based professional services firm closed most recently at $191.67 a share. That's below the above purchase price. It's also more than 31% higher than the year-to-date low during the pandemic panic selling back in March.In addition, note that there was some amount of insider buying at Boston Properties, Inc. (NYSE: BXP), General Motors Company (NYSE: GM), Harley-Davidson Inc (NYSE: HOG) and Penn National Gaming, Inc (NASDAQ: PENN) and last week as well.Keep up with all the latest breaking news and trading ideas by following Benzinga on .See more from Benzinga * Notable Insider Buys This Past Week: Peloton, Illinois Tool Works And More(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Bausch Health Announces Pricing And Upsize Of Private Offering Of Senior Notes And Prepayment Of Term Loan 2022 Mandatory Amortization
    PR Newswire

    Bausch Health Announces Pricing And Upsize Of Private Offering Of Senior Notes And Prepayment Of Term Loan 2022 Mandatory Amortization

    Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") announced today that it has priced and upsized its previously announced offering of $1,500,000,000 aggregate principal amount of 6.250% senior notes due 2029 (the "Notes"). The size of the offering reflects an increase of $250,000,000 in aggregate principal amount of the Notes from the previously announced offering size of $1,250,000,000. The Notes will be sold to investors at a price of 100% of the principal amount thereof.

  • MarketWatch

    Bausch Health launches offering of $1.25 billion in senior notes that mature in 2029

    Bausch Health Cos. Inc. , the company formerly known as Valeant, said Monday it has launched an offering of $1.25 billion of new senior notes that mature in 2029. Proceeds will be used to fund the redemption of existing 6.50% senior secured notes that mature in 2022 and to pay related fees. Shares were down 1.4% premarket and have fallen 44% in the year to date, while the S&P 500 has fallen 9%.

  • Bausch Health Announces Launch of Private Offering of Senior Notes and Conditional Redemption of Existing Senior Secured Notes
    PR Newswire

    Bausch Health Announces Launch of Private Offering of Senior Notes and Conditional Redemption of Existing Senior Secured Notes

    Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") announced today that it has launched an offering of $1,250,000,000 aggregate principal amount of new senior notes due 2029 (the "Notes"). Bausch Health intends to use the proceeds from the offering of the Notes, along with cash on hand, to fund the conditional redemption (the "Redemption") of its existing 6.50% Senior Secured Notes due 2022 (the "Existing Notes") and to pay related fees, premiums and expenses.

  • Bausch Health Companies Inc. (BHC) Q1 2020 Earnings Call Transcript
    Motley Fool

    Bausch Health Companies Inc. (BHC) Q1 2020 Earnings Call Transcript

    Participating on today's call are Chairman and Chief Executive Officer, Mr. Joe Papa; and Chief Financial Officer, Mr. Paul Herendeen. In addition to this live webcast, a copy of today's slide presentation and a replay of this conference call will be available on our website under the Investor Relations section.

  • Bausch (BHC) Down on Q1 Earnings & Sales Miss, View Trimmed
    Zacks

    Bausch (BHC) Down on Q1 Earnings & Sales Miss, View Trimmed

    Bausch (BHC) misses on earnings and sales in the first quarter and lowers guidance due to the coronavirus pandemic.

  • Investopedia

    Biotech Funds Could Rally to New Highs

    Biotech funds have rallied within striking distance of multi-year resistance and could break out in coming weeks.

  • Endo (ENDP) Q1 Earnings Beat on Coronavirus-Led Stockpiling
    Zacks

    Endo (ENDP) Q1 Earnings Beat on Coronavirus-Led Stockpiling

    Endo's (ENDP) earnings and sales beat estimates in the first quarter owing to increased customer inventory purchasing due to the COVID-19 pandemic

  • Coronavirus update: U.S. death toll tops 74,000, as Trump administration shelves ‘too cautious’ CDC guide to reopening
    MarketWatch

    Coronavirus update: U.S. death toll tops 74,000, as Trump administration shelves ‘too cautious’ CDC guide to reopening

    The number of U.S. fatalities from the coronavirus that causes COVID-19 climbed above 73,000 on Thursday, as President Donald Trump’s administration said it is shelving recommendations from the Centers for Disease Control and Prevention on reopening safely because they were too cautious

  • Bausch Health (BHC) Q1 Earnings and Revenues Miss Estimates
    Zacks

    Bausch Health (BHC) Q1 Earnings and Revenues Miss Estimates

    Bausch (BHC) delivered earnings and revenue surprises of -1.11% and -1.68%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

  • MarketWatch

    Bausch Health's stock drops after a surprise decline in revenue and lowered outlook

    Shares of Bausch Health Companies Inc. sank 3.6% in premarket trading Thursday, after the drug and medical-device products maker reported a wider net loss and a surprise decline in revenue given the negative effects of the COVID-19 pandemic. The net loss was $152 million, or 43 cents a share, after a loss of $52 million, or 15 cents a share, in the year-ago period, primarily because of decreases in tax benefits. The FactSet consensus for net loss per share was 35 cents. Excluding non-recurring items, adjusted net income fell to $316 million from $358 million; the company did not provide an adjusted per-share figure. Revenue fell to $2.012 billion from $2.016 billion, while the FactSet consensus was for a rise to $2.032 billion, as revenue was negatively impacted by about $35 million by the COVID-19 pandemic. For 2020, the company lowered its revenue guidance range to $7.80 billion to $8.20 billion from $8.65 billion to $8.85 billion, which compares with the FactSet consensus of $8.40 billion. The stock has dropped 39.2% over the past three months through Wednesday, while the S&P 500 has declined 14.4%.

  • Bausch Health Companies Inc. Announces First-Quarter 2020 Results
    CNW Group

    Bausch Health Companies Inc. Announces First-Quarter 2020 Results

    Bausch Health Companies Inc. Announces First-Quarter 2020 Results

  • As Shopify Passes RBC, Canada Market Curse Gets Put to Test
    Bloomberg

    As Shopify Passes RBC, Canada Market Curse Gets Put to Test

    (Bloomberg) -- Shopify Inc. surged on Wednesday to become Canada’s most valuable company -- but can the e-commerce giant survive being No. 1?Ottawa-based Shopify edged past Royal Bank of Canada to become the largest publicly listed company in Canada. The achievement comes with a dubious distinction, however: those that leapfrogged the value of Canada’s largest bank in the past have faltered.Royal Bank, incorporated in 1869, has been Canada’s most valuable company for years, but has been been eclipsed on a few occasions. Shopify closed with a market value of C$121.3 billion ($85.6 billion), surpassing Royal Bank’s C$120.5 billion.The last company to surpass Royal Bank’s market capitalization was drugmaker Valeant Pharmaceuticals International Inc. in July 2015. Months later, the value of the Quebec-based company plunged amid controversies over business practices, accounting and drug pricing. Valeant has since been renamed Bausch Health Companies Inc. and has new management and a different ticker symbol.Before that, BlackBerry Ltd. --- the inventor of the smartphone and then known as Research in Motion Ltd. -- crossed Royal Bank briefly in 2007. It held the top spot for about five months in 2008, before Apple Inc.’s iPhone and other handset makers rose up to steal its market away.Further back, Nortel Networks Corp. became the biggest Canadian company in 2000, swelling to a market value of C$366 billion and accounting for as much as 35% of Canada’s benchmark index, before crashing in the tech wreck. The telecommunications-equipment maker ultimately filed for bankruptcy in 2009 and was liquidated.The dramatic collapse of two Canadian tech giants in a country more known for being hewers of wood and drawers of water has hung over the country’s corporate psyche for years. So Shopify’s rise has been cheered on by many.“I think it’s obvious in hindsight the leadership of both those companies got disconnected from their underlying markets,” said Eric Jackson, founder of a Toronto-based tech-focused hedge fund EMJ Capital Ltd., referring to BlackBerry and Nortel.Jackson believes Shopify “should be held up as a poster child for what Canada should be trying to encourage in it’s tech sector because it’s been remarkable what they’ve done,” he said. Jackson had owned the company’s stock but doesn’t currently have a position. Its U.S.-listed shares have risen by 43 times since the initial public offering at $17 in 2015.Too Fast?This year’s rally, which has seen the stock double, has drawn its doubters.“On just about any valuation metric, this is one of the most expensive stocks in Techland,” Mark Mahaney, an analyst at RBC Capital Markets in San Francisco told clients in a note Wednesday. Shopify also holds the highest sales multiple, though has the largest sales growth outlook, RBC added. The bank rates Shopify with the equivalent of a buy.The rally has made founder and chief executive officer Tobi Lutke, Canada’s fourth-richest person, according to the Bloomberg Billionaires Index. The 39-year-old has added $2.8 billion to his wealth this year, and is now worth $6.3 billion. The billionaire has about 7% of Shopify, according to its 2019 proxy circular.Lutke, a German immigrant with vivid blue eyes and a penchant for tweed caps, began building software to launch an online snowboard store in 2004. It became obvious that the software was more valuable than the snowboards, according to his website profile, and he went on to launch the Shopify platform in 2006. RBC was incorporated in 1869.Shopify sells tools to help companies set up an online, a business model seen flourishing during the coronavirus pandemic that has shuttered bricks and mortar stores. In April, the company’s chief technology officer tweeted Shopify was handling “Black Friday-level traffic every day” to bring thousands of businesses online.Amazon ComparisonAt Bloomberg’s Sooner Than You Think conference in New York last year, Lutke said Shopify isn’t competing with Amazon.com Inc. but helping other people do so.“They’ve obviously become the anti-Amazon, they’re all about empowering everybody else except Amazon on the online e-commerce world to be successful and they’ve expanded and expanded their suite of services,” Jackson said.He believes Shopify has the opportunity to keep rising and have a market value of several hundred billion dollars in the years ahead.“They are still just getting going. People who complain they are ‘too expensive’ don’t understand how much revenue and profits they’ll drive in the years ahead,” Jackson said.(Updates with new information on value of Lutke’s stake, gain since IPO.)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

  • Should You Buy Bausch Health (BHC) Ahead of Earnings?
    Zacks

    Should You Buy Bausch Health (BHC) Ahead of Earnings?

    Bausch Health (BHC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

  • Bausch Health And Alfasigma Announce Resolution Of XIFAXAN® Intellectual Property Litigation
    CNW Group

    Bausch Health And Alfasigma Announce Resolution Of XIFAXAN® Intellectual Property Litigation

    LAVAL, Quebec , May 6, 2020 /CNW/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") along with its wholly owned subsidiary, Salix Pharmaceuticals ("Salix"), which is one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases, together with Salix's licensor Alfasigma SpA (collectively the "Salix Parties"), have agreed to resolve the outstanding intellectual property litigation with Sandoz Inc., regarding XIFAXAN ® (rifaximin) 550 mg tablets. The Salix Parties will grant Sandoz a non-exclusive license effective Jan. 1, 2028 to its intellectual property relating to XIFAXAN 550 mg tablets in the United States .